While still under active clinical development for different hematological malignancies [11], fatal side effects occurred in the KEYNOTE-B79 phase Ib trial with allogeneic NKG2D-CAR T cells in colorectal cancer (NCT04991948; clinicaltrials.gov), and patient recruitment was discontinued. The gene discussed is KLRK1; the disease is hematologic disorder.